-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Drop in Short Interest
Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Drop in Short Interest
Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Rating) saw a large drop in short interest in December. As of December 30th, there was short interest totalling 288,200 shares, a drop of 31.9% from the December 15th total of 423,100 shares. Based on an average trading volume of 428,700 shares, the days-to-cover ratio is currently 0.7 days.
Plus Therapeutics Trading Down 2.3 %
PSTV traded down $0.01 during midday trading on Friday, hitting $0.43. 206,454 shares of the company were exchanged, compared to its average volume of 493,002. The firm has a market capitalization of $14.45 million, a P/E ratio of -0.48 and a beta of 0.42. Plus Therapeutics has a 1-year low of $0.29 and a 1-year high of $1.20. The firm's 50 day moving average price is $0.38 and its 200-day moving average price is $0.50. The company has a quick ratio of 2.81, a current ratio of 2.81 and a debt-to-equity ratio of 0.36.
Get Plus Therapeutics alerts:Plus Therapeutics (NASDAQ:PSTV – Get Rating) last announced its earnings results on Thursday, October 20th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02. The company had revenue of $0.07 million for the quarter. As a group, equities analysts forecast that Plus Therapeutics will post -0.75 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in PSTV. Otter Creek Advisors LLC increased its position in Plus Therapeutics by 293.5% in the 2nd quarter. Otter Creek Advisors LLC now owns 330,168 shares of the company's stock valued at $178,000 after buying an additional 246,267 shares in the last quarter. Vanguard Group Inc. increased its position in Plus Therapeutics by 20.0% in the 1st quarter. Vanguard Group Inc. now owns 855,264 shares of the company's stock valued at $855,000 after buying an additional 142,417 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Plus Therapeutics by 50.1% during the 2nd quarter. Renaissance Technologies LLC now owns 101,093 shares of the company's stock worth $55,000 after purchasing an additional 33,735 shares in the last quarter. 10.52% of the stock is owned by institutional investors.Analyst Ratings Changes
Separately, Jonestrading assumed coverage on Plus Therapeutics in a report on Thursday, October 6th. They set a "buy" rating and a $5.00 target price on the stock.
Plus Therapeutics Company Profile
(Get Rating)
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Recommended Stories
- Get a free copy of the StockNews.com research report on Plus Therapeutics (PSTV)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
加上治疗公司(纳斯达克:PSTV-GET评级)看到空头股数在12月份大幅下降。截至12月30日,空头股数共有28.82万股,较12月15日的42.31万股下降了31.9%。以428,700股的平均成交量计算,目前天数与回补比率为0.7天。
Plus Treeutics股价下跌2.3%
PSTV在周五午盘交易中下跌0.01美元,触及0.43美元。该公司成交量为206,454股,而其平均成交量为493,002股。该公司的市值为1,445万美元,市盈率为-0.48,贝塔系数为0.42。Plus Treeutics的一年低点为0.29美元,一年高位为1.20美元。该公司的50日移动均线价格为0.38美元,200日移动均线价格为0.50美元。该公司的速动比率为2.81,流动比率为2.81,债务权益比为0.36。
到达Plus Treeutics警报:Plus Treateutics(纳斯达克代码:PSTV-GET Rating)上一次公布财报是在10月20日星期四。该公司公布本季度每股收益(0.19美元),比普遍预期的(0.21美元)高出0.02美元。该公司本季度的收入为70万美元。作为一个整体,股票分析师预测,Plus Treateutics本财年的每股收益将达到0.75欧元。
机构资金流入和流出
几家对冲基金最近调整了他们在PSTV的头寸。Otter Creek Advisors LLC在第二季度将其在Plus Treateutics的地位增加了293.5%。Otter Creek Advisors LLC现在拥有330,168股该公司的股票,价值17.8万美元,上个季度又购买了246,267股。先锋集团在第一季度将其在Plus治疗公司的地位增加了20.0%。先锋集团(Vanguard Group Inc.)目前持有855,264股该公司股票,价值855,000美元,上一季度又购买了142,417股。最后,复兴科技有限责任公司在第二季度增持了50.1%的Plus Treateutics股份。复兴科技有限责任公司现在持有101,093股该公司股票,价值55,000美元,上个季度又购买了33,735股。10.52%的股票由机构投资者持有。分析师评级发生变化
另外,Jones Trading在10月6日星期四的一份报告中承担了Plus治疗公司的报道。他们为该股设定了“买入”评级和5.00美元的目标价。
PLUS治疗公司简介
(获取评级)
Plus Treateutics,Inc.是一家临床阶段的制药公司,专注于癌症和其他疾病患者治疗药物的开发、制造和商业化。它的主要候选药物是Rhenium-186纳米脂质体,这是一种针对中枢神经系统癌症的专利放射治疗,包括复发的胶质母细胞瘤、软脑膜转移瘤和儿童脑癌。
推荐故事
- 免费获取StockNews.com关于Plus Treateutics(PSTV)的研究报告
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
获得《Plus Treateutics Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Plus Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧